Chromium (Picolinate)
Trace mineral that enhances insulin signaling and may improve glucose metabolism. Picolinate form offers better bioavailability.
Projected serum levels — 200 mcg (≈ 0.20 mg), once daily
Maintenance schedule: 200 mcg (≈ 0.20 mg) once daily (oral).
Loading schedule: 600 mcg on day 1, then 200 mcg (≈ 0.20 mg) once daily — reaching therapeutic levels sooner.
Modeled steady state after ~79 days: peak ≈ 0.16 mg, trough ≈ 0.16 mg body load. Population-based estimate over 121 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Mineral
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 30 days
- Common dose
- 200 mcg (≈ 0.20 mg)
- Suggested maximum
- 1k mcg/day
- Reference dose range
- 100–1k mcg (single dose)
- Suggested cadence
- once daily
Documented interactions
-
caution
Alendronate (Fosamax) + Chromium (Picolinate)
Alendronate (Fosamax) (bisphosphonate) forms insoluble complexes with Chromium (Picolinate) in the GI tract, reducing absorption of both.
-
caution
Armour Thyroid (Desiccated Thyroid Extract) + Chromium (Picolinate)
Armour Thyroid (Desiccated Thyroid Extract) (thyroid hormone) forms insoluble complexes with Chromium (Picolinate) in the GI tract, reducing absorption of both.
-
caution
Berberine + Chromium (Picolinate)
Both chromium and berberine enhance insulin sensitivity and lower blood glucose.
-
caution
Metformin + Chromium (Picolinate)
Chromium enhances insulin sensitivity. Combined with metformin, may cause hypoglycemia.
Serum checks 4 modeled interaction pairings for chromium (picolinate) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.
Research behind this entry
-
Chromium picolinate supplementation for overweight or obese adults
Cochrane review found chromium picolinate produced a statistically significant but clinically small reduction in body weight (average 1.1 kg) compared to placebo.
-
Beneficial effects of chromium(III) on glucose and lipid metabolism in patients with type 2 diabetes mellitus
RCT in 180 type 2 diabetic patients found 1000 mcg/day chromium picolinate significantly reduced HbA1c, fasting glucose, and total cholesterol over 4 months.
-
Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials
Systematic review of 22 trials found limited evidence that chromium supplementation improves glucose or lipid metabolism in non-diabetic individuals, with stronger evidence in diabetics.
-
A double-blind, placebo-controlled, exploratory trial of chromium picolinate in atypical depression: effect on carbohydrate craving.
This citation reports a human clinical study involving Chromium (Picolinate). It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.
4 published studies referenced in the app, each with a plain-language summary.